-
ASH 2024 | Dr. David John Lewis: Is a Chemotherapy-Free Era for Mantle Cell Lymphoma Approaching?
Dr. David John Lewis: I am a hematology consultant based in Plymouth, UK, with a primary clinical and research focus on lymphoma. I work at a center specializing in early-phase…
-
ASH 2024 | Dr. David J. Kuter on the Potential of a Novel BTK Inhibitor in Adult ITP Treatment
1. Challenges in ITP Treatment for Adults Hematology Frontier: ITP remains a challenging condition, especially in adult patients. Could you outline the primary hurdles in managing ITP in this population?…
-
2025 CASH丨Dr. Suning Chen: Focusing on Annual Advances in AML—Integrating Innovation for a Better Future
The 5th Annual Meeting of Chinese Alliance for Societies of Hematology (2025 CASH) was held in Tianjin from January 3 to 5, featuring the theme of “Comprehensive Hematology, Comprehensive Health, and Comprehensive Well-being.” The event invited top hematology experts from China and abroad to discuss the latest advancements and future trends in the field.
-
2025 CASH丨Dr. Rong Fu: Interpretation of the PNH China Guidelines
The 5th Annual Meeting of Chinese Alliance for Societies of Hematology (2025 CASH) was held in Tianjin from January 3 to 5, under the theme “Comprehensive Hematology, Comprehensive Health, and Comprehensive Well-being.” Top hematology experts from China and abroad were invited to discuss the latest advancements and future trends in hematology.
-
ASH 2024 | Dr. Paul Monagle on Pediatric Deep Vein Thrombosis (VTE): Epidemiology, Updated Guidelines, and Treatment Recommendations
1. Epidemiology and Mechanisms of Pediatric VTE Hematology Frontier: Pediatric deep vein thrombosis (VTE) is relatively rare but shows an increasing trend. Could you elaborate on the epidemiology and underlying…
-
2025 CASH丨Another Milestone! Dr. Jing Pan’s Team Recognized in the Top 10 Hematology Research Advancements of 2024
From January 3–5, 2025, the 5th Annual Meeting of Chinese Alliance for Societies of Hematology (CASH) was held in Tianjin under the theme “Comprehensive Hematology, Comprehensive Health, and Comprehensive Well-being.” As a key highlight of the conference, the Top 10 Hematology Research Advancements of 2024 were announced during the closing ceremony, recognizing significant scientific achievements…
-
Annual Review | Prof. Jun Ma: 2024 Updates on Guidelines and Advances in Acute Lymphoblastic Leukemia (ALL)
In recent years, the field of hematologic oncology has witnessed remarkable breakthroughs, with acute lymphoblastic leukemia (ALL) emerging as a focal point of progress. Chinese researchers have made significant contributions, driving milestone advancements in both research and clinical practice. To usher in the new year, Hematology Frontier invited Professor Jun Ma from the Harbin Institute…
-
Dr. Hongwei Yao: Organ Preservation and Survival in Mid-Low Rectal Cancer with Radiotherapy and PD-1 Inhibitors
Oncology Frontier: Could you explain the unique value of combining long-course radiotherapy with PD-1 inhibitors in neoadjuvant therapy for mid-to-low rectal cancer? What advantages has this treatment strategy shown in…
Connecting Medical Expertise through Media